|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,886.00 GBX | -0.29% |
|
+0.59% | +3.37% |
| 12/05 | European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading | MT |
| 12/05 | Artios Pharma Limited and GSK Enter Clinical Trial Collaboration Agreement | CI |
| Capitalization | 7.55TCr 10TCr 8.72TCr 7.99TCr 14TCr 9,76900Cr 14TCr 95TCr 37TCr 4,63600Cr 38TCr 37TCr 16,11300Cr | P/E ratio 2026 * |
11.8x | P/E ratio 2027 * | 11.1x |
|---|---|---|---|---|---|
| Enterprise value | 8.79TCr 12TCr 10TCr 9.3TCr 16TCr 11,37100Cr 16TCr 1,10700Cr 43TCr 5,39600Cr 45TCr 44TCr 18,75600Cr | EV / Sales 2026 * |
2.6x | EV / Sales 2027 * | 2.4x |
| Free-Float |
92.31% | Yield 2026 * |
3.7% | Yield 2027 * | 3.87% |
Last Transcript: GSK plc
| 1 day | -0.42% | ||
| 1 week | +0.59% | ||
| Current month | -2.20% | ||
| 1 month | -13.09% | ||
| 3 months | -12.89% | ||
| 6 months | +4.17% | ||
| Current year | +3.37% |
| 1 week | 1,822 |  | 1,897.36 |
| 1 month | 1,822 | | 2,202 |
| Current year | 1,774 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +5.24% | 3.15% | 27 M€ | |
| +13.09% | 2.51% | 12 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.29% | +0.59% | +38.88% | +28.33% | 10TCr | |
| +2.54% | +2.83% | +36.05% | +133.60% | 88TCr | |
| +2.76% | +2.58% | +55.23% | +44.42% | 54TCr | |
| +0.31% | +1.85% | +11.07% | +42.45% | 37TCr | |
| +1.33% | -1.00% | +20.39% | +10.73% | 33TCr | |
| +0.13% | +1.47% | +35.23% | +14.72% | 29TCr | |
| +0.78% | +1.00% | +29.63% | +26.28% | 28TCr | |
| +0.66% | +0.23% | +48.53% | -2.19% | 28TCr | |
| +0.91% | +2.12% | -31.78% | -48.50% | 21TCr | |
| +0.18% | +1.70% | +24.51% | +44.20% | 18TCr | |
| Average | +0.90% | +1.15% | +26.77% | +29.40% | 34.56TCr | |
| Weighted average by Cap. | +1.40% | +0.65% | +30.74% | +50.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.38TCr 4.56TCr 3.9TCr 3.57TCr 6.25TCr 4,36900Cr 6.29TCr 43TCr 17TCr 2,07300Cr 17TCr 17TCr 7,20600Cr | 3.54TCr 4.78TCr 4.09TCr 3.74TCr 6.55TCr 4,57900Cr 6.59TCr 45TCr 17TCr 2,17300Cr 18TCr 18TCr 7,55200Cr |
| Net income | 635.35Cr 858.88Cr 733.48Cr 672.05Cr 1.18TCr 82TCr 1.18TCr 8TCr 3.12TCr 39TCr 3.22TCr 3.16TCr 1,35600Cr | 671.85Cr 908.22Cr 775.62Cr 710.66Cr 1.24TCr 87TCr 1.25TCr 8.46TCr 3.29TCr 41TCr 3.41TCr 3.34TCr 1,43400Cr |
| Net Debt | 1.24TCr 1.67TCr 1.43TCr 1.31TCr 2.29TCr 1,60200Cr 2.3TCr 16TCr 6.07TCr 76TCr 6.28TCr 6.15TCr 2,64300Cr | 948.82Cr 1.28TCr 1.1TCr 1TCr 1.76TCr 1,22800Cr 1.77TCr 12TCr 4.65TCr 58TCr 4.81TCr 4.71TCr 2,02500Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/26/13 | 1,886.00 p | -0.29% | 43,93,959 |
| 12/26/12 | 1,891.50 p | +2.55% | 1,21,15,790 |
| 11/26/11 | 1,844.50 p | +0.08% | 93,14,552 |
| 08/26/08 | 1,843.00 p | -0.83% | 61,09,465 |
| 07/26/07 | 1,858.50 p | -0.88% | 1,49,43,290 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition